QIAGEN strengthens its portfolio for cancer research, showcasing latest product launches at AACR Annual Meeting 2024
April 03 2024 - 4:05PM
QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today
announced a series of new products to further enhance cancer
research as well as to enable urine collection and stabilization as
a new approach for liquid biopsy.
These three new products, along with the IVD
version of QIAGEN’s digital PCR platform QIAcuity set for launch in
mid-2024, are to be featured at the annual meeting of the American
Association for Cancer Research (AACR) in San Diego, California,
from April 5-10. Two Exhibitor Spotlight Theater sessions and
several poster presentations will highlight additional advances
from QIAGEN in this field.
“We are excited to share our latest innovation
in digital PCR, NGS, and non-invasive sample collection and DNA
stabilization with the research community that will help them gain
valuable insights into cancer. Our new QIAcuity PanCancer kits will
enhance the understanding of EGFR- and BRAF-driven cancers while
our QIAcuity IVD system, ready for launch this summer, will
translate cancer research into clinical applications and
precision diagnostics,” said Nitin Sood, Senior Vice President and
Head of QIAGEN’s Life Sciences Business Area. “And with our new
solutions for urine liquid biopsy and targeted RNA-sequencing,
researchers receive new efficient tools that potentially enable
them to better detect minimal residual disease, monitor treatment
response, and identify new therapeutic targets.
The new products involve the
following:
-
The newly launched QIAcuity dPCR PanCancer Kits will allow
researchers using QIAGEN’s QIAcuity dPCR system to detect multiple
EGFR and BRAF hallmark mutations at the same time and with high
sensitivity. EGFR and BRAF are genes essential for normal cell
growth and function, but mutations in these genes can result in
cancer development. The assays clearly discriminate between
wild-type and mutant sequences, enhancing specificity and reducing
false positives. Researchers can use the kits for pre-screening
samples before, for example, analyzing them with NGS, or monitoring
cancer cells. Simultaneously assessing the mutations, they reduce
time and cost and save on sample material. The technology has the
potential to be adapted to identify other genes associated with
cancer risks.
“I am testing the novel PanCancer Assays on the
QIAcuity instrument using FFPE tissue samples and liquid biopsies
to concurrently detect multiple hallmark mutations in BRAF and EGFR
– and initial findings have convinced me that this product has the
potential to accelerate prognostic and predictive biomarker
analysis, early mutation detection and screenings,” said
Vijayalakshmi Ramshankar, Professor and Head of the Department of
Preventive Oncology Research, Cancer Institute (WIA), Chennai,
India.
-
To advance research on how the immune system interacts with cancer,
QIAGEN has introduced the QIAseq Targeted RNA-seq Panel for
T-cell receptors. T-cell receptors play a crucial role in the
adaptive immune system, which is responsible for recognizing and
eliminating abnormal cells, such as cancer cells. The panel uses
unique molecular indices (UMI) with QIAseq Enrichment Technology to
facilitate ultrasensitive and accurate characterization of the
immune repertoire in human and mouse from low input and FFPE
samples. It enables targeted NGS detection of the human or mouse
expressed T cell receptors (TCR): TCR-alpha, TCR-beta, TCR-gamma
and TCR-delta. This library prep kit will accelerate research into
several areas with high accuracy and sensitivity, among them how
the T-cell receptor repertoire in cancer can be used as a biomarker
and how the repertoire of tumor-infiltrating T-cells can improve
the understanding of tumor behavior.
-
The PAXgene Urine Liquid Biopsy Set currently being
developed by PreAnalytiX, a QIAGEN and BD joint venture, will
launch later this year. It will provide an easy-to-use,
non-invasive sampling approach to liquid biopsy and address current
preanalytical workflow gaps for cell-free DNA in urine (ucfDNA). By
introducing preservatives into urine samples, it will prevent the
rapid, post-collection degradation of ucfDNA and minimize the
release of potentially misleading genomic DNA, both of which can
make ucfDNA analysis unreliable or even impossible. Urine liquid
biopsy research holds significant potential for applications such
as detecting minimal residual disease, monitoring treatment
response and identifying therapeutic targets, complementing the
results of blood plasma analysis and offering a more comprehensive
understanding of the tumor.
Professor Ellen Heitzer of the Diagnostic and
Research Institute of Human Genetics at the Medical University of
Graz in Austria will present the results of her study with the
PAXgene technology in an Exhibitor Spotlight Theater session:
“Cell-free DNA isolated from urine offers a truly non-invasive
sampling method for liquid biopsy, but ucfDNA requires careful
sample handling. The urine collection and stabilization solution
enables optimized standardized workflows. This makes several
downstream analyses feasible with ucfDNA and can provide important
complementary information.”
QIAGEN will also highlight at the AACR meeting
the upcoming launch of the QIAcuity system for IVD testing – the
expansion of its digital PCR technology from research to the
clinical setting. The QIAcuityDx system offers a custom assay
development environment alongside IVD functionality, providing labs
with a simplified yet regulatory-compliant route to run IVD assays
or lab-developed tests (LDTs) and generate results within the same
working day.
Learn more about QIAGEN’s offering at the AACR
Annual Meeting 2024, (booth #922 in the San Diego Convention
Center) and poster presentations highlighting new solutions in
digital PCR, NGS and preanalytical workflows at
https://www.qiagen.com/applications/cancer-research/aacr-2024-annual-meeting.
About PreAnalytiX, GmbH
PreAnalytiX was formed in 1999 by QIAGEN and BD with the purpose
of developing, manufacturing, and marketing integrated systems for
the collection, stabilization, and purification of nucleic acids
(DNA and RNA) for molecular diagnostic testing. More information
about PreAnalytiX can be found at https://www.preanalytix.com.
About QIAGEN
QIAGEN N.V., a Netherlands-based holding
company, is the leading global provider of Sample to Insight
solutions that enable customers to gain valuable molecular insights
from samples containing the building blocks of life. Our sample
technologies isolate and process DNA, RNA and proteins from blood,
tissue and other materials. Assay technologies make these
biomolecules visible and ready for analysis. Bioinformatics
software and knowledge bases interpret data to report relevant,
actionable insights. Automation solutions tie these together in
seamless and cost-effective workflows. QIAGEN provides solutions to
more than 500,000 customers around the world in Molecular
Diagnostics (human healthcare) and Life Sciences (academia, pharma
R&D and industrial applications, primarily forensics). As of
December 31, 2023, QIAGEN employed approximately 6,000 people
in over 35 locations worldwide. Further information can be found at
http://www.qiagen.com.
Forward-Looking Statement
Certain statements contained in this press
release may be considered forward-looking statements within the
meaning of Section 27A of the U.S. Securities Act of 1933, as
amended, and Section 21E of the U.S. Securities Exchange Act of
1934, as amended. To the extent that any of the statements
contained herein relating to QIAGEN's products, timing for launch
and development, marketing and/or regulatory approvals, financial
and operational outlook, growth and expansion, collaborations,
markets, strategy or operating results, including without
limitation its expected adjusted net sales and adjusted diluted
earnings results, are forward-looking, such statements are based on
current expectations and assumptions that involve a number of
uncertainties and risks. Such uncertainties and risks include, but
are not limited to, risks associated with management of growth and
international operations (including the effects of currency
fluctuations, regulatory processes and dependence on logistics),
variability of operating results and allocations between customer
classes, the commercial development of markets for our products to
customers in academia, pharma, applied testing and molecular
diagnostics; changing relationships with customers, suppliers and
strategic partners; competition; rapid or unexpected changes in
technologies; fluctuations in demand for QIAGEN's products
(including fluctuations due to general economic conditions, the
level and timing of customers' funding, budgets and other factors);
our ability to obtain regulatory approval of our products;
difficulties in successfully adapting QIAGEN's products to
integrated solutions and producing such products; the ability of
QIAGEN to identify and develop new products and to differentiate
and protect our products from competitors' products; market
acceptance of QIAGEN's new products and the integration of acquired
technologies and businesses; actions of governments, global or
regional economic developments, weather or transportation delays,
natural disasters, political or public health crises, and its
impact on the demand for our products and other aspects of our
business, or other force majeure events; as well as the possibility
that expected benefits related to recent or pending acquisitions
may not materialize as expected; and the other factors discussed
under the heading “Risk Factors” contained in Item 3 of our most
recent Annual Report on Form 20-F. For further information, please
refer to the discussions in reports that QIAGEN has filed with, or
furnished to, the U.S. Securities and Exchange Commission.
Source: QIAGENCategory: Corporate
John Gilardi
QIAGEN N.V.
+49 2103 29 11711
ir@qiagen.com
Domenica Martorana
QIAGEN N.V.
+49 2103 29 14637
ir@qiagen.com
Thomas Theuringer
QIAGEN N.V.
+49 2103 29 11826
pr@qiagen.com
Daniela Berheide
QIAGEN N.V.
+49 2103 29 11676
pr@qiagen.com
Qiagen NV (NYSE:QGEN)
Historical Stock Chart
From Apr 2024 to May 2024
Qiagen NV (NYSE:QGEN)
Historical Stock Chart
From May 2023 to May 2024